Shire's Intuniv gets the nod in US

Pharmaceutical firm Shire has received approval from US regulators for its extended-release hyperactivity drug Intuniv, and expects it to be available in US pharmacies in November. The company, which is Britain’s third largest drugmaker, is also pinning its hopes on a new human genetic therapies division that makes medicines to treat a range of rare diseases.